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ABSTRACT 
 
 
 
 The two primary differences between normal epithelial cells and cancerous cells are the 
ability of cancerous cells to metastasize and avoid apoptosis. The drug 4-methylthio-2-
oxobutyric acid (MTOB) has been shown to interact with the CtBP transcription repressor 
causing the induction of apoptosis, as well as a reduction in migration of cells. The focus of this 
MQP was to explore the most efficacious use of MTOB through the study of structural analogs, 
as well as combination therapy with CtBP siRNA. While structural analogs seemed to be less 
effective than similar doses of MTOB, using siRNA against CtBP2 in combination with low 
doses of MTOB proved to significantly lower cell growth rate and increase apoptosis.  
Immunoblotting analysis also demonstrated a sizeable decrease in expression of the CtBP2 
protein with the combination MTOB/siRNA treatment. 
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BACKGROUND 
 
 
Current Treatments for Cancer and Their Downfalls 
The most common current cancer therapies available are toxins that kill cancer cells. In 
most cases these toxins target cancer cells only slightly more than normal cells, and in some 
cases don’t really target cancer cells at all, meaning that normal cells are also affected. This is 
the most prominent downfall to cancer therapies and the reason that cancer continues to be such 
a potent killer. Most chemotherapies work by targeting rapidly proliferating cells, such as cancer 
cells, however the human body contains a great number of other cells that grow quickly such as 
blood cells forming in bone marrow, cells in the digestive tract, reproductive organ cells, and 
hair follicles (Sadanandam, et al., 2010). These effects on normal cells sometimes explain lethal 
side effects of chemotherapy.  
 Chemotherapy is not the only method to treat cancer. Today there are a variety of drugs 
on the market that have less harsh side effects than chemotherapy. While they are often used in 
conjunction with chemo, they are also primarily effective in only a small handful of neoplasms. 
Despite all forms of cancer having some common traits, each type of cancer has certain 
differentiating factors such as the expression of specific marker proteins, or the inactivation of 
tumor supressors such as p53 (Sadanandam, et al., 2010). Often different types of neoplasms 
have very different signal transduction pathways that are involved in growth stimulation, 
therefore the most effective cancer therapies are those which target proteins that are involved in 
most if not all types of cancer.  
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C-Terminal Binding Proteins and Their Role in Cancer 
 C-terminal binding proteins (CtBP) are transcriptional factors that are an important part 
of the normal cell’s ability to selectively allow for cell migration while avoiding apoptosis. 
While these functions are necessary to a small extent in normal cells, it is these primary 
mechanisms that make cancer so dangerous. It has been found that in particular that CtBP2 is 
highly upregulated in a large number of cancer types. This protein is localized to the nucleus of a 
cell and acts as a transcriptional corepressor of several genes in apoptotic, anti-migratory, and 
anti-cellular proliferation pathways. (Figure-1). Due to its ability to allow many of the critical 
traits of cancer to flourish, it is a prime target for a therapeutic agent.  
 
 
 
 
 
 
Figure-1:  The Role of CtBP2 in Cancer Formation.  Transcription factor 
CtBP is known to block the expression of apoptotic genes (increasing cell 
survival) (diagram center) and block gp15 and p16 cell cycle arrest proteins, 
leading to cell proliferation (diagram right), while stimulating MDM2 to block 
tumor suppressor p53 (diagram left).  CtBP2 acts as a transcriptional 
corepressor of BH3 apoptotic genes, as well as various tumor suppressors such 
as p15
INK41
, p16
INK4b
. This diagram also shows the activation of MDM2, an 
inhibitor of p53 dependant apoptosis, by CtBP2 (Paliwal, et al. 2007).    
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 CtBP targets several groups of genes, many of which were crucial to this project, 
including genes directly related to cell proliferation and apoptosis. CtBP2 regulates apoptosis in 
large part by repressing the expression of pro-apoptotic BH3 a genes. These include genes such 
as Bik, Puma, and NOXA, which are known to powerfully regulate the induction of apoptosis. 
CtBP2 inhibits these genes allowing for the increase in cell survival for many cells that would 
normally undergo apoptosis. (Chinnadurai, 2009) This is one of the many ways in which CtBP 
assists in the survival of cancer cells. Additionally, CtBP is an activator of MDM2, which 
inhibits p53, a vital protein for apoptosis in many cells, but furthermore CtBP directly inhibits 
p53 independent apoptosis as well (Paliwal, et. al 2006). CtBP therefore effectively inhibits a 
number of important apoptotic pathways, making the inhibition of CtBP a promising new area 
for cancer therapy research. 
 Uncontrolled cellular proliferation is a crucial component of cancerous cells. The genes 
p16
INK4a
 and p15
INK4b
 directly affect proliferation of cells by causing G1 phase cell cycle arrest, 
making them cell cycle inhibitors. In many forms of cancer, CtBP inhibits these genes, allowing 
for unregulated proliferation (Kovi, et. al 2010). By inhibiting these genes, CtBP allows for an 
increase in cellular mitosis, which allows for rampant growth for cancer cells.  
 
4-Methylthio-2-Oxobutyric Acid (MTOB) and its Interaction with CtBP2 
 The compound 4-methylthio-2-oxobutyric acid (MTOB) is naturally occurring in the 
human body. In particular, it is the penultimate compound in the methionine-salvage pathway 
(Tang et al., 2006). In addition to its involvement in that pathway however, the Grossman Lab at 
the University of Massachusetts Medical School discovered that MTOB is able to bind to CtBP2 
via the dehydrogenase domain causing the repression of its activity (Straza, Kovi, Paliwal, 
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Messina, Trench, & Grossman, submitted). Previous studies by this lab have shown that MTOB 
alone is able to induce apoptosis in vitro and also inhibit cell migration and proliferation. The 
suppression of CtBP2, and the absence of toxicity, makes MTOB a wonderful lead compound for 
therapeutic research. 
 
Analog Compounds of MTOB 
 The method of most pharmaceutical companies use to take a lead drug from a lead to a 
product is to select the most pharmacologically effective analog of the drug through a process 
called high-throughput screening. This was similar to the purpose of this project, on a much 
smaller scale. By examining structural analogs of MTOB it may be possible to find a chemical 
with a similar or better ability to bind CtBP2, and additionally lower the compound’s expense for 
production. The major issues with the use of MTOB as a therapeutic agent primarily reside in its 
expense, and the high dosages at which it is most effective.  
This project focused on using two different analogous compounds to test their efficacy in 
comparison to MTOB. These compounds are 4-methylthio-2-hydroxybutyric acid (MTHB) and 
L-phenyllactate (Figure-2). These compounds vary only slightly from MTOB. Where MTOB 
has a ketone adjacent to the carboxyl group (alpha ketoacid), MTHB has a hydroxyl group 
(Summers, et al., 1998). In the case of phenyllactate, a phenyl ring replaces the thioester at the 
end of the carbon chain (Collier, Butler, & Mitch, 1980).  
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 MTHB is also involved in the methionine-salvage pathway in the body, and therefore 
also makes a great potential MTOB-like drug due to its similarity to MTOB and its apparent lack 
of toxicity. In solid form it is stored with a calcium salt where there are two molecules of MTHB 
for every one of CaCl2 (Tang, Kadariya, Murphy, & Kruger, 2006). L-phenyllactate by itself has 
been only minimally studied, but one study showed phenyllactate to increase growth in normal 
and germ-free rats eating a phenylalanine-free diet (Collier, Butler, & Mitch, 1980). Both of 
these compounds were studied alongside MTOB to compare their ability to suppress CtBP2  by 
way of studying cell proliferation and viability.  
 
siRNA Technology and its Applications 
Another area of interest for this project was to examine the use of CtBP2 specific siRNA 
treatment in combination with lower concentrations of MTOB. The technology behind using 
Figure-2. The Chemical Structures of MTOB, MTHB, and L-Phenyllactate The 
above figure shows the structural differences between MTOB and its analog 
compounds MTHB and Phenyllactate (Tang et al., 2006; Collier et al., 1980).  
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small interfering RNA to silence gene expression at the translational level has only existed for a 
relatively short amount of time. SiRNA transfection is a process by which small segments of 
RNA designed to conjugate to specific target mRNAs within the cell are inserted in order to 
silence the target gene (Dykxhoorn, Novina, & Sharp, 2003). This is done through the use of 
micro RNA fragments that can conjugate to the target mRNA (Figure-3). Once these miRNA 
fragments conjugate, the now dsRNA is targeted by an RNA-induced silencing complex, or 
RISC, for degradation. Through this process of targeted conjugation and degradation a 
knockdown of the target gene is accomplished (Long, et al., 2010).  
 
 
 
 
 This siRNA technology has proven effective at silencing genes that code for the 
expression of proteins that assist in the growth and metastasis of cancer cells. Using a siRNA 
Figure-3. siRNA Treatment.  The above graphic shows the 
process through which siRNA silences targeted gene 
expression at the translational level (Dykxhoorn, et al. 
2003).  
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specific to the gene that codes for CtBP2 should allow for a decrease in the expression of CtBP2, 
promoting apoptosis and decreasing cell proliferation. While there is currently no in vivo 
delivery methods that would allow for the use of siRNA technology as a therapeutic agent in 
mouse or human models, that topic is being researched (Sorensen & Sioud, 2010). Using this 
technology in conjunction with MTOB treatment could prove to be a very effective and targeted 
cancer therapeutic.  
 12 
PROJECT PURPOSE 
 
 
The need for a targeted and effective cancer drug with limited toxicity to healthy cells is 
evident. While MTOB is a promising cancer treatment that has shown promise against a variety 
of a cancer cells in vitro, it also presents difficulties due to its high cost at effective doses. The 
purpose of this Major Qualifying Project was to take this therapeutic agent, and explore the use 
of its various structural analogs, in combination with siRNA treatments against a known tumor-
inducing transcription factor CtBP2, to increase the efficacy of the drug.  The hypothesis tested 
in this project was that an MTOB analog, or a combination treatment including a CtBP2-specific 
siRNA knockdown, could work as effectively or more effectively than MTOB alone.  It was also 
the intention to find methods that could reduce the effective dosage of MTOB to reduce the 
overall cost of treatment.  
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METHODS 
 
Cell Culture 
Cell Lines 
 The two cell lines used for the combination siRNA and MTOB treatments were H1299 
and U20s cells. H1299 cells were originally isolated from a non-small cell lung carcinoma 
metastasized to a lymph node, and these cells are p53 negative. U2OS cells were originally 
isolated from an osteosarcoma, and are p53 positive.  For the colony assays done to test the 
comparative efficacy of MTOB analogs, the HCT116 -/- cell line (HCT-/-) was also used.  HCT 
-/- cells are a line of human colorectal carcinoma cells which have a targeted deletion of both 
p53 alleles, making them p53 negative. Each of these cell lines was originally provided by Mike 
Straza, and later H1299 and U20S cells were provided by Roman Kulikov (PhD).  
 
Cell Subculture and Plating 
 For the H1299 and U20S cell lines, high glucose DMEM media supplemented with 10% 
Fetal Bovine Serum (FBS) and 1% Penicillin Streptomycin (Pen Strep) was used for culture 
inside of BD falcon T25 culture flasks.  For HCT-/- cells, McCoy’s Media supplemented with 
10% FBS and 1% Pen Strep was used for culture inside of T25 flasks as well. When 
subculturing, after the media was aspirated off the cells, each flask was washed with Phosphate 
Buffered Saline (PBS), and then 0.5 ml of trypsin for was incubated with the cells for 3-5 
minutes to remove the adherent cells. 5.0 ml of medium was used to deactivate the trypsin, and 
then the proper dilution ratio was used to either plate or re-culture cells into flasks. 
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Cell Treatments 
 A 40 mM stock of each of the compounds used was created in each of the medias used 
for each cell line. For MTOB, 62 mg of MTOB was added per 10 mL of each media. In the case 
of MTHB, 136 mg of the compound was used for 10 ml of media, 66 mg was used for Phenyl 
Lactate, and 59 mg was used for CaCl2. Each solution was then mixed until dissolved, and 
filtered into a new 15ml falcon tube.  The resulting 40 mM solution was stored at 4
o
C for use for 
up to 7 days. The media was then diluted in a separate 15ml falcon tube for each dilution needed, 
and 2 ml of the proper concentration was added to the corresponding well for each assay. 
 
Colony Assays and Cell Staining 
 The cell lines U20S and HCT -/- were used for this assay. The assay was performed by 
plating 100,000 cells/well into each well of a 6-well plate.  The cells were then allowed to adhere 
and grow for 24 hours. These cells were then treated in duplicate with varying doses of either 
MTOB, MTHB, L-phenyl lactate, or 2 ml of compound-free media for the control. Because 
MTHB is stored in CaCl2, there are two molecules of MTHB for every molecule of CaCl2 
meaning that the concentrations used actually indicate double that concentration of MTHB. After 
72 hours of compound treatment, the medium was aspirated, and 2 ml of fresh compound-free 
medium was added to the wells. After 4 days of recovery, the cells were fixed to the 6-well 
plates in order to be stained.  
 For fixing the cells to the plates, the medium was first aspirated off the cells, and they 
were then washed with 2 ml of cold PBS for each well. 2 ml of a solution of 70% methanol and 
30% glacial acedic acid was then added to each well, and plates were placed at -20
o
C for 15-20 
minutes. The fixing solution was then removed from the wells, and the wells were allowed to dry 
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completely before staining. Giemsa stain was added at a 1:5 dilution with diH20 from the 
commercially available stock solution at a volume of 2 ml per well. The stain was allowed to 
stay on the wells for 5-10 minutes before being rinsed repeatedly, submerging the 6-well plate 
into water. The plates were then stored at room temperature. Photographs of stained wells were 
taken by a 10-megapixel camera. 
 
siRNA Transfection 
 The siRNA transfections were performed by first incubating 4 µl of oligofectamine per 
single well reaction with 24 µl of MEM serum-free medium for 10 minutes at room temperature 
in a culture hood. After this period, a combination of 3 µl of either control (scramble) siRNA or 
CtBP2 specific siRNA, and 97 µl of MEM serum free medium was added to the oligofectamine 
reaction mix, and allowed to incubate for an additional 30 minutes. After this incubation period, 
the full 128 µl reaction was added drop wise to 2 ml of the appropriate medium in each of the 
wells to be treated with siRNA, while gently swirling the media in the wells.  
 
Combination siRNA and MTOB Treatments 
 H1299 and U20S cells were both used with this assay. The cells were plated in 6-well 
plates at noted concentrations (either 30,000 or 15,000 cells per well) and allowed to grow for 24 
hours. These plates were then transfected with either control (scramble) siRNA, or CTBP2 
siRNA using the protocol discussed above. The siRNA treatment was taken off the cells by 
aspirating the media at either 12 or 24 hours, which is noted in the results. After aspirating the 
siRNA media, the cells received either fresh media for the controls or siRNA alone, or they were 
treated with medium containing a specific concentration of MTOB, most often at 1mM. The cells 
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were left to grow with the treated media with MTOB or the control media for 72 hours, at which 
point the viability assay was run using Trypan Blue (protocol below).  Figure-4 shows a 
representation of the plating process with an image of each of the compounds and controls used 
in the assay. 
 
 
 
 
 
 
 
 
Viability Assays with Trypan Blue 
 Cell viability was determined using a Trypan blue assay on the cells collected from each 
well after 72 hours of treatment. The supernatant was removed and collected from each well, and 
the wells were washed with a very small quantity of trypsin to deactivate the cells. After 
deactivation, the cells were trypsinized, and each well was scraped to remove all the adherent 
cells. 0.5 ml of PBS was used to wash the wells and ensure all the cells were collected.   An 
aliquot of the cell suspension diluted 1:1 with Trypan blue was placed into a hemocytometer to 
count live and dead cells.  Each well was counted with three separate counts. The remaining 
unstained cells were lysed using 1 ml of lysis buffer. These lysates were used in to perform 
Figure 4.  Design of the Six Well Plate Layout for the Combination of 
siRNA and MTOB Treatments. 
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western blots.  Prior to being tested for viability, the plates were photographed at 200x 
magnification to illustrate the differences between the wells. 
 
Western Blotting 
 Using a Bradford Assay, protein concentrations from the lysates mentioned above were 
determined. These concentrations were used to normalize the amount of protein loaded into each 
well of a 4-12% polyacrylamide gel. Transfer was performed to a nitrocellulose membrane. After 
being washed overnight in 5% milk, the membranes were probed with CtBP2 and GAPDH as a 
primary antibody, and subsequently washed with a mouse secondary antibody and developed 
with enhanced chemiluminescence reagents.  
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RESULTS 
 
 
 The overall purpose of this project was to find a more effective method of treating cancer 
cells through either siRNA treatments, and/or treatments with analog compounds of MTOB. This 
study was conducted by performing a variety of viability-based assays, such as the trypan blue 
assay and colony assay.  
 
Viability Assays Using siRNA and MTOB on U20S Cells 
 Figure 5 shows the effect of CtBP2 siRNA alone and in combination with 1 mM MTOB. 
This image was taken at 200X magnification, and shows a typical grouping of cells in each of the 
6-well plates. For all the U20S plates used for this assay the siRNA treatment remained on the 
cells for 24 hr, and the MTOB for 72 hr. The microscopy indicated that the combined treatment 
inhibited cell division best. 
 
 
Figure 5. CtBP2 siRNA Combination Treatment with MTOB in U2OS Cells.  The 
above images show the Untreated (A), 1 mM MTOB (D), Control siRNA (B), Control 
siRNA with 1 mM MTOB (E), CtBP2 siRNA (C), CtBP2 siRNA with 1 mM MTOB (F). 
These wells were plated at 30,000 cells/well, treated with siRNA for 24 hours, then treated 
with 1mM MTOB for 72 hours. 
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 Figure-6 shows the normalized data for each repeat of this U2OS viability assay. It 
clearly shows the combined treatment works best, both on cancer cell viability (percentage of 
cells that are living versus those that are dead), and on cell numbers (number of cells in each well 
compared to the control).  
 
 
 
 
 
 
 
 Whole cell lysates were prepared from the U2OS cells collected at the end of the viability 
assay for immunoblot analysis to determine expression of the CtBP2 protein to see if protein 
expression differed from the CtBP2 siRNA-treated cells, and those treated with CtBP2 siRNA in 
combination with MTOB.  Figure-7 is a gel image chosen in which the cells were treated with 2 
mM MTOB, but this image was quite similar to all other immunoblots run using this cell line. 
The primary antibodies for this assy included CtBP2, and GAPDH as a positive control. Both 
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Figure 6. Normalized Viability Data for U2OS Cell Assays.  The above graph shows 
the viability of U20S cells treated with CtBP2 or control siRNA with or without MTOB 
for 24 hours, as quantified by a trypan blue viability assay. The percentage of live versus 
dead cells is shown, in addition to the percentage of cell numbers compared to the control. 
The histobars represent the mean of 3 experiments.  Error bars denote standard error. 
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were developed with a mouse secondary antibody.  The data indicate that the CtBP2 signal is 
lowest in the cells treated with both MTOB and CtBP2 siRNA. 
 
 
 
 
 
 
Viability Assays Using siRNA and MTOB on H1299 Cells 
 The most notable difference between the H1299 assays and the ones performed on U20S 
cells was the amount of time the siRNA treatment was performed on the cells. Because oligo-
fectamine, used in the siRNA transfection, has some cell toxicity, a change in the protocol was 
made to allow for a shorter incubation time.  This allowed for the analysis of the effect of 
oligofectamine on the cells, as well as a comparison of efficacy of the siRNA when the delivery 
time is shortened.  Figure 8 shows the effect of the various treatments via a microscopy images 
taken at 200X magnification. This image is a good representation of what other plates that 
underwent the same protocol looked like after the 72 hour compound treatment period.  As with 
Figure 7. Western Blot of CtBP2 Protein Expression.  
The above images show the total cellular levels of CtBP2 
and GAPDH in U20S cells treated with various 
combinations of CtBP2 siRNA and 2 mM MTOB. The 
Western Blot was probed for CtBP2 protein, and for 
GAPDH as a positive control.  
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the p53-positive U2OS cells, the p53-negative H1299 cells showed the least cell numbers in the 
combined MTOB/siRNA treatment. 
 
 
 
 
 
 The H1299 viability data is quantified in Figure 9.   As with the U2OS cells, the least 
number of cells and lowest tumor viability is observed for the combined treatment.   
Figure 8. Microscopy of Various Treatments on H1299 Cells. The above images show: 
Untreated (A), 1 mM MTOB (D), Control siRNA (B), Control siRNA with 1 mM MTOB (E), 
CtBP2 siRNA (C), and CtBP2 siRNA with 1mM MTOB (F). These wells were plated at 
30,000 cells/well, treated with siRNA for 12 hours, then treated with 1mM MTOB for 72 
hours. 
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 H1299 lysates were used to run Western Blots to determine expression of the CtBP2 
protein to see if the CtBP2 levels differed with the various treatments (Figure-10).  The primary 
antibodies for this gel included CtBP2, and GAPDH as a positive control. Both were developed 
with a mouse secondary antibody.   As was observed for the U2OS cells, the weakest CtBP2 
band occurred with the combined treatment. 
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Figure 9. Normalized Viability Data for H1299 Cells.  The above graph shows the 
viability of H1299 cells treated with CtBP2siRNA for 12 hours as quantified by a trypan 
blue viability assay. The percentage of live versus dead cells is shown in addition to the 
percentage of cell numbers compared to the control.  Histobars denote the mean of 3 
experiments.  Error bars denote standard error. 
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Colony Assays Using U20S Cells Treated with Analog MTHB 
 The U20S colony assays were plated with 10,000 cells/ well for each of the 6-well plates. 
After the 72-hour compound treatment, and 4-day cell recovery period, the cells were fixed and 
stained.  Figure 11 shows a photograph of one of the duplicate sets of treatments from a 6-well 
plate treated with two concentrations (4 mM and 10 mM) of MTOB, to serve as a control to 
compare with the analog MTHB.  
 
 
 
 
Figure 10. Western Blot of CtBP2 Protein Expression in Treated 
H1299 Cells.  The above images show the CtBP2 protein levels in 
H1299 cells treated with 1mM MTOB.  The Western Blot was probed 
for CtBP2 protein, and GAPDH as a positive control.  
 
Figure 11. Colony Assay of U2OS with MTOB Treatment.  The 
wells are from a colony assay with 72 hour treatments of control media, 
4 mM MTOB, and 10 mM MTOB, left to right, respectively. 
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 Figure-12 shows a photograph of one of the duplicate sets of treatments from a 6-well 
plate treated with two concentrations (4 mM and 8 mM) of analog MTHB.  Due to the CaCl2 in 
the solid stored form of MTHB, the negative control includes 4 mM CaCl2 which is the amount 
of CaCl2 present in the 8 mM MTHB treatment.  
 
 
 
 
 
 
 
 
Colony Assays Using HCT -/- Cells Treated with MTHB and Phenyllactate 
 The HCT -/- colony assays were plated with 100,000 cells/well for each of the 6-well 
plates.  After the 72-hour compound treatment, and 4-day cell recovery period, the cells were 
fixed and stained.  Figure-13 shows a photograph of one of the duplicate sets of treatments from 
a 6-well plate treated with decreasing concentrations (4 mM and 1 mM) of MTOB, to serve as a 
control to compare against the analog compounds MTHB and Phenyllactate.  
 
Figure 12. Colony Assay of U2OS with MTHB Treatment. The wells 
above are from a colony assay with 72-hour treatments of control media 
with 4 mM CaCl2, 4 mM MTHB, and 8 mM MTHB, left to right,  
respectively. 
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 Figure-14 shows a photograph of the fixed and stained MTHB-treated plates in the same 
increasing concentrations of 4 and 8 mM, as the previous figure. The control used here was the 
same 4 mM CaCl2 used in the U20S cell line.  
 
  
Figure 13. Colony Assay of HCT Cells with MTOB Treatment.  The 
wells above are from a colony assay with 72-hour treatments of control 
media, 4 mM MTOB, and 1 mM MTOB, left to right, respectively. 
 
Figure 14. Colony Assay of HCT Cells with MTHB Treatment.  The wells 
above are from a colony assay with 72-hour treatments of control media with 4 
mM CaCl2, 4 mM MTHB, and 8 mM MTHB, left to right, respectively. 
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 Figure-15 shows the effect of Phenyllactate on HCT -/- cells using increasing 
concentrations (4 and 10 mM).  The control on this experiment was media with no compounds 
added, as with the MTOB treatments. 
 
 
 
 
 
 
 
 
 
  
Figure 15. Colony Assay of HCT Cells with Phenyllactate Treatment.  The 
wells above are from a colony assay with 72 hour treatments of control media, 4 
mM Phenyl Lactate, and 10 mM Phenyl Lactate, left to right, respectively. 
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DISCUSSION 
 
 
 
Primary Conclusions 
 
 The data from this project shows that a combination treatment using CtBP2 siRNA and 
MTOB is markedly more effective than either treatment alone, and the particular analog 
compounds tested were not as efficacious as MTOB in the same doses. Figures 6 and 9 heavily 
support the primary hypothesis of the effect of a combination treatment providing incredibly 
promising results for enhancing the efficacy of MTOB in future experiments.  
 Additionally, the expression levels of CtBP2 as demonstrated by the western blot films in 
Figures 7 and 10 show a noticeable CtBP2 protein decrease in the CtBP2 siRNA lane, and 
surprisingly even more so in the combination CtBP2siRNA and MTOB lanes. While this 
expression decrease is not so striking in the H1299 blot due to uneven protein loading of the 
wells, it is certainly more convincing in Figure 7 with the U20S line.  
 This is a fascinating conclusion, as the research done on the interaction between MTOB 
and CtBP2 would not lead to a change in the expression of CtBP2, but rather just inhibit the 
protein’s ability to bind and affect the anti-migratory and apoptotic pathways in cells. While this 
could indicate a great number of things, and requires further investigation, a likely conclusion 
would be that in binding to CtBP2 (seemingly more so in the presence of CtBP2 siRNA in which 
there is less CtBP2 to bind, increasing the ratio of MTOB to CtBP2), MTOB in some way 
destabilized the protein causing degradation. If this were the case, it would make this treatment 
option even more effective as it would be combating not only the binding of CtBP2, but also the 
problem of its up-regulation.  
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 The analog compounds in this study did not perform as effectively as desired. The 
process of finding effective and efficient pharmacological analogs of a lead compound is a very 
difficult process, and one that can take pharmaceutical companies years. The two used in this 
study were beneficial in their comparably low cost and similar structure, however when 
examining the colony assays, it is very clear that the amount of each analog needed to obtain 
equivalent cytotoxic effects is far greater than that of MTOB, making them poor agents for a 
deliverable drug. While MTOB and these analogs have a unique benefit in cancer therapy of 
being relatively harmless to normal cells, which is drastically different than most treatments such 
as chemotherapy, any drug in such large doses still presents problems with delivery and cost.  
 
Problems Faced and Questions Raised 
 One of the most significant problems that arose throughout the project was the 
adjustment of the protocol for the siRNA transfections and treatments to combat 
oligofectamine’s toxicity to normal cells. While siRNA has had countless beneficial applications 
to the field of research, there is currently much discussion and research focused on viable 
delivery methods for this technology, as no current delivery method exists for in vivo 
experiments.  One adjustment that was made to lower the toxicity was the amount of 
oligofectamine used, which was lowered from 6 µl to the 4 µl used for the experiments presented 
in this project. The other was the amount of time that the cells were exposed to the siRNA 
treatment.  In Figures 6 and 9, there is a strong difference between the percentages of cells 
present in the control siRNA well compared to the control between U20S (treated for 24 hours) 
and H1299 (treated for 12). This would indicate a decreased toxicity effect by the 
oligofectamine, while the shortened exposure time does not appear to impact the potency of the 
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siRNA itself.  However this lethality comparison cannot be limited to the difference in siRNA 
treatment time alone as they are two separate cell lines, which vary in their robustness.  
 Most of the other problems encountered throughout the project were limited to some 
normal trial and error. However, a particular issue that stands out stemmed from the 
effectiveness of the combined siRNA and CtBP2 experiment. As can be seen in Figures 5 and 8, 
the wells with the combination treatments were so impacted that the normal method of spinning 
down cells to form a pellet prior to performing the trypan blue assay was not possible. Because 
of this, the volume that the cells were suspended in was greater than desired, making for a 
greater degree of variance between trials due to lower cell numbers in the 10 µl samples. This 
did not pose a tremendous issue, as the effect was very similar in all trials, and the standard 
deviation was not too great. 
 
Future Experiments 
 The Grossman lab has already discussed the possibility of injecting mice with the CtBP2 
siRNA both alone and as a combination therapy with MTOB, though there is still a great deal of 
research needed before this combination therapy could be used in any human clinical testing. 
More analog compounds will be tested, in addition to testing some combination treatments with 
MTOB and analogs using a Trypan Viability Assay. More repeats of the experiments shown in 
this project will be conducted to enhance the quality of the data.  There is of course more to be 
researched before MTOB can be brought to trials, however multiple studies have confirmed that 
it is a promising lead compound for anticancer therapy. 
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